Progress report on the first sub-Saharan Africa trial of newer versus older antihypertensive drugs in native black patients by Augustine N Odili et al.
TRIALS
Odili et al. Trials 2012, 13:59
http://www.trialsjournal.com/content/13/1/59RESEARCH Open AccessProgress report on the first sub-Saharan Africa
trial of newer versus older antihypertensive drugs
in native black patients
Augustine N Odili1,2, Birinus Ezeala-Adikaibe1,3, Mouhamadou B Ndiaye5, Benedict C Anisiuba3, Marius M Kamdem4,
Chinwuba K Ijoma3, Joseph Kaptue4, Hilaire J Boombhi6, Philip M Kolo7, Elvis N Shu8, Lutgarde Thijs1,
Jan A Staessen1,9*, Babatunde A Omotoso7, Samuel Kingue6, Serigne A Ba5, Daniel Lemogoum4,
Jean-René M’Buyamba-Kabangu10, Ifeoma I Ulasi3 and on behalf of the Newer versus Older Antihypertensive
Agents in African Hypertensive Patients (NOAAH) investigatorsAbstract
Background: The epidemic surge in hypertension in sub-Saharan Africa is not matched by clinical trials of
antihypertensive agents in Black patients recruited in this area of the world. We mounted the Newer versus Older
Antihypertensive agents in African Hypertensive patients (NOAAH) trial to compare, in native African patients, a
single-pill combination of newer drugs, not involving a diuretic, with a combination of older drugs including a
diuretic.
Methods: Patients aged 30 to 69 years with uncomplicated hypertension (140 to 179/90 to 109 mmHg) and ≤2
associated risk factors are eligible. After a four week run-in period off treatment, 180 patients have to be
randomized to once daily bisoprolol/hydrochlorothiazide 5/6.25 mg (R) or amlodipine/valsartan 5/160 mg (E). To
attain blood pressure <140/<90 mmHg during six months, the doses of bisoprolol and amlodipine should be
increased to 10 mg/day with the possible addition of up to 2 g/day α-methyldopa.
Results: At the time of writing of this progress report, of 206 patients enrolled in the run-in period, 140 had been
randomized. At randomization, the R and E groups were similar (P≥ 0.11) with respect to mean age (50.7 years),
body mass index (28.2 kg/m2), blood pressure (153.9/91.5 mmHg) and the proportions of women (53.6%) and
treatment naïve patients (72.7%). After randomization, in the R and E groups combined, blood pressure dropped by
18.2/10.1 mmHg, 19.4/11.2 mmHg, 22.4/12.2 mmHg and 25.8/15.2 mmHg at weeks two (n = 122), four (n = 109),
eight (n = 57), and 12 (n = 49), respectively. The control rate was >65% already at two weeks. At 12 weeks, 12
patients (24.5%) had progressed to the higher dose of R or E and/or had α-methyldopa added. Cohort analyses of
49 patients up to 12 weeks were confirmatory. Only two patients dropped out of the study.
Conclusions: NOAAH (NCT01030458) demonstrated that blood pressure control can be achieved fast in Black
patients born and living in Africa with a simple regimen consisting of a single-pill combination of two
antihypertensive agents. NOAAH proves that randomized clinical trials of cardiovascular drugs in the indigenous
populations of sub-Saharan Africa are feasible.
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Sub-Saharan Africa faces an unprecedented epidemic of
cardiovascular disease [1-3]. Hypertension is the main
driver of cardiovascular complications. Whereas high
blood pressure almost did not exist in Black Africa in
the first half of the twentieth century [4], hypertension
now affects between 30% and 60% of African Blacks [5].
Lowering blood pressure and controlling hypertension is
key to cardiovascular disease prevention.
Practice guidelines issued by the World Health
Organization and the International Society of Hyperten-
sion (WHO/ISH) in 2003 recommended that a low dose
diuretic should be considered as the first choice of ther-
apy on the basis of comparative trial data, availability
and cost [6]. Several randomized clinical trials published
since 2003, proved that a combination of newer antihy-
pertensive agents, compared with older antihypertensive
agents [7] or combinations including a diuretic [8], low-
ered blood pressure more with fewer metabolic side-
effects and, more importantly, further reduced the risk
of cardiovascular complications. Because trials of antihy-
pertensive drug treatment are scarce in Black patients
born and living in Africa, we recently mounted the
Newer versus Older Antihypertensive agents in African
Hypertensive Patients (NOAAH) trial (NCT01030458)
to compare the efficacy of single-pill combinations of
newer versus older antihypertensive agents [9]. This
NOAAH progress report describes recruitment and
baseline characteristics of the randomized patients and
the blood pressure control after randomization as part
of the ongoing efforts invested in quality assurance and
control and in providing feedback to the clinical investi-
gators and building capacity to run randomized clinical
trials of antihypertensive drugs in this part of the world.
Methods
The detailed protocol of the NOAAH trial has been
published elsewhere [9]. NOAAH is an investigator-
led trial conducted at seven sub-Saharan centers, six
of which enrolled patients. NOAAH complies with the
guidelines for good clinical practice outlined in the
Helsinki declaration [10]. Each participating center
received approval from the local Institutional Review
Board and, if applicable, from National Regulatory
Authorities. The Sponsor (Hypertension Unit, Univer-
sity of Kinshasa Hospital, Democratic Republic of
Congo) obtained ethical approval from the Ethics
Committee of the Faculty of Medicine.
Selection of patients
Eligible patients are treatment naïve or previously trea-
ted patients of either sex with grade-1 or grade-2 hyper-
tension [11]. Age must range from 30 to 69 years.
Women with childbearing potential must apply effectivecontraception. Hypertension must be uncomplicated
with a maximum of two additional risk factors, as
defined in the 2007 guidelines [11] of the European
Societies of Cardiology and Hypertension (ESC/ESH). A
history of cardiovascular disease, electrocardiographic
left ventricular hypertrophy and diabetes mellitus were
exclusion criteria. The blood pressure determining eligi-
bility is the average of three consecutive readings
obtained with patients in the seated position after at
least four weeks follow-up off antihypertensive treat-
ment. Blood pressure must range from 140 to 179 mmHg
systolic and from 90 to 109 mmHg diastolic. The stand-
ing systolic blood pressure, the average of three consecu-
tive readings obtained immediately after the sitting
measurements, must be at least 110 mmHg.
The presence of three or more risk factors, a history of
cardiovascular disease or diabetes mellitus [12] are ex-
clusion criteria. Previously treated patients should not
have a compelling indication according to the ESC/ESH
guidelines [11] to continue antihypertensive drug treat-
ment and should not take more than a single drug or
one single-pill combination at the enrollment visit.
Other exclusion criteria include: atrial fibrillation; elec-
trocardiographic left ventricular hypertrophy with strain
pattern or electrocardiographic left ventricular hyper-
trophy defined as a Sokolow-Lyon index larger than
38 mm (3.8 mV) or a Cornell voltage × duration QRS
index larger than 2,440 mm×msec [13-15]; renal dys-
function defined as a serum creatinine concentration
higher than 1.4 mg/dL in women or 1.5 mg/dL in men
[16]; proteinuria or hematuria as detected by a semi-
quantitative dipstick test; severe non-cardiovascular
disorders; psychiatric illness; and substance abuse.
Design
The study starts with a screening visit, at which
informed consent is obtained, followed by a run-in
period with two subsequent visits at two-week intervals.
Investigators keep a log of the patients screened for en-
rollment. Patients entering the run-in period provide
informed consent. Literate patients sign and date the
informed consent form. Illiterate patients provide a fin-
gerprint in the presence of an independent witness, who
also has to sign the consent form. At the screening visit,
antihypertensive drug treatment is discontinued and life-
style changes are recommended and reinforced at the
subsequent run-in visits.
Study forms are emailed to the Studies Coordinating
Center (SCC, Leuven, Belgium). After checking the eligi-
bility criteria and the quality and completeness of the
run-in forms, SCC randomizes patients in a 1:1 propor-
tion, using permuted blocks of four consecutive patients
within each center. Patients are randomly allocated to a
single-pill combination of 6.25 mg hydrochlorothiazide
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hydrochlorothiazide plus 10 mg bisoprolol (LodozW,
Merck Serono) in the reference group or to the combin-
ation of amlodipine 5 mg plus valsartan 160 mg to be
up-titrated to amlodipine 10 mg with valsartan 160 mg
(ExforgeW, Novartis) in the experimental group. In the
two treatment groups, α-methyldopa (AldometW) up to
2 g per day is used, if the blood pressure remains uncon-
trolled on the maximally tolerated dose of the rando-
mized medication. After randomization, patients are
followed up for six months with visits scheduled after
two weeks and four weeks and monthly thereafter until
the end of the study.
The primary outcome is the between-group difference
in the change in systolic blood pressure achieved on ran-
domized treatment and measured with the patient in the
seated position [9]. Secondary outcomes are the time
interval required after randomization to achieve blood
pressure control defined as a level below 140 mmHg
systolic and 90 mmHg diastolic, the incidence of adverse
events (including metabolic side effects), and the adher-
ence to the study medication and drop-out rate [9]. To
demonstrate a 5-mmHg between-group difference in the
achieved systolic blood pressure (SD, 12 mmHg) with a
2-sided P-value of 0.01 and 90% power, 180 randomized
patients, 90 per treatment group, are required [9].
Measurements
Blood pressure is measured by means of validated [17]
oscillometric OMRON 705IT recorders (OMRON
Healthcare Europe BV, Nieuwegein, Netherlands)
according to the ESC/ESH guideline [18]. Use of auto-
mated devices allows blinded assessment of the blood
pressure endpoints in an open trial, in which neither
patients nor investigators are blinded with regard to
treatment allocation. A standard cuff with an inflat-
able bladder of 22 × 12 cm will be used if arm
circumference is less than 32 cm and cuffs with a
35 × 15 cm bladder on larger arms. Investigators rec-
ord standard 12-lead electrocardiograms by means of
the paperless Cardiax device (http://www.rdsm.eu/
cardiax.html), interfaced with a computer. Biochem-
ical measurements include hemoglobin, hematocrit,
red and white blood cell counts, serum potassium,
creatinine and total cholesterol, blood glucose, and a
dipstick test on fresh urine to detect glucosuria, pro-
teinuria and hematuria. To assess side effects, we used
a simple two-page questionnaire, which we validated
in previous studies [19,20].
Drug accountability
SCC shipped LodozW, ExforgeW and AldometW to the
recruiting clinical sites. To track the flow of medication,
each box of drugs carries a unique identificationnumber. Patients should return unused medication at
the next visit. Investigators count the number of unused
pills. Patients are classified as compliant, if they took at
least 80% of the prescribed study medication and if they
did not miss any dose on the days of the clinic visits.
Whenever drugs are dispensed or recouped investigators
complete a drug accountability form to be forwarded to
SCC.
Database management and statistical analysis
SCC developed the case report forms as interactive PDF
forms, which investigators complete at the clinical sites
and print for the local patient files. XML files exported
from the PDFs are sent to SCC as email attachments.
After quality control and addition of the codes for symp-
toms, diseases and concurrent medications at SCC, the
XML files are directly imported into the SAS database,
using the SAS XML Mapper, version 9.2.
For database management and statistical analyses, we
used SAS 9.3 (SAS Institute, NC, USA). In this report,
we compared means and proportions by Student’s t test
and χ2 statistic, respectively. Statistical significance is a
two-sided P value of 0.05.
Results
This report is based on the data available at SCC on 14
April 2011. At this point (Figure 1), 237 patients had
been screened, 206 had been enrolled into the four week
run in period, and 69 and 71 had been randomized to
control (hydrochlorothiazide plus bisoprolol) or experi-
mental treatment (valsartan plus amlodipine), respect-
ively. Figure 2 gives the number of patients screened,
enrolled in the run-in phase, and randomized. The max-
imum follow up varied, because the patients had been
enrolled over several months starting on 1 September
2010. The number of patients with a follow-up of two
weeks and one, two, three and four months was 122,
109, 57, 49 and 24, respectively; the proportion of adher-
ent patients at these visits was 89.6%, 76.7%, 76.4%,
73.2% and 83.3%, respectively.
Patient characteristics at baseline
In all 140 patients, age at randomization averaged
50.7 ± 8.9 years, ranging from 30.5 to 68.9 years. The un-
treated blood pressure measured in the sitting position
at the end of the run-in period was 153.9 ± 11.3 mmHg
systolic and 91.5 ± 9.9 mmHg diastolic; the correspond-
ing measurements in the standing position were
154.5 ± 13.2 mmHg and 97.3 ± .9.9 mmHg, respectively.
Of the 140 randomized patients, 75 (53.6%) were
women.
Among the 75 women, average values of the anthropo-
metric measurements were 162.6 ± 6.9 cm for height,
76.7 ± 13.6 kg for body weight, 29.0 ± 5.1 kg/m2 for body
Figure 1 Trial profile based on data available on 14 April 2011.
Odili et al. Trials 2012, 13:59 Page 4 of 11
http://www.trialsjournal.com/content/13/1/59mass index, and 92.2 ± 13.1 cm for waist circumference;
the corresponding values in the 65 men were
172.0 ± 7.2 cm, 81.3 ± 15.3 kg, 27.4 ± 4.4 kg/m2, and
95.3 ± 12.2 cm, respectively.
Table 1 shows that the patients randomized to the
control and experimental treatments had similar charac-
teristics (P ≥ 0.11). Of the 140 participants, four (2.9%; 0
women and four men) were current smokers, none
snuffed tobacco, and 44 (31.6%; 12 women and 32 men)
reported regular drinking. In drinkers, the median alco-
hol consumption was 7.1 g per day (interquartile range,
2.9 to 11.4).
The number of participants with measurements of
hemoglobin, hematocrit, glucose, cholesterol and cre-
atinine are 62, 67, 67, 69 and 68 in the older drug group
and 65, 68, 71, 68 and 71 in the newer-drug group. CI,
confidence interval; ECG, electrocardiogram; n, number;
SD, standard deviation.
Follow-up after randomization
In the two treatment groups combined, at 12 weeks of
follow-up, only ten patients (20.4%) had progressed tothe higher dose of the reference or the experimental
treatment of whom four had α-methyldopa added. In an
additional two patients α-methyldopa was added to the
lower dose of the study medication. None of the patients
had crossed over.
Table 2 lists the blood pressure levels at various
lengths of follow-up. Systolic and diastolic pressures
decreased (P< 0.001) after randomization by 18.2 and
10.1 mmHg at two weeks (n = 122); 19.4 and 11.2 mmHg
at one month (n = 109); 22.4 and 12.2 mmHg at two
months (n = 57); and 25.8 and 15.2 mmHg at three
months (n = 49). On average, the reduction in blood
pressure from randomization to the last available visit in
129 patients was 22.1 mmHg systolic and 12.4 mmHg
diastolic (Table 2 and Figure 3). A cohort analysis of 49
patients, who had blood pressure measurements at each
time point from randomization up to two months was
confirmatory (Figure 4). Already starting from the sec-
ond week after randomization, the control rates of
hypertension were over 65%.
Side effects led to premature termination of the trial
in two patients: insomnia, asthenia and hot flushes in
Figure 2 Number of patients screened, enrolled and
randomized on 14 April 2011. The horizontal dotted line indicates
the number of patients to be randomized.
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In addition, in three patients the study medication was
adjusted because of heartburn, tiredness and diarrhea.
Discussion
NOAAH is the first multicenter clinical trial on antihy-
pertensive therapies that is exclusively running in sub-
Saharan Africa. The underlying hypothesis is that in
Blacks born and living in Africa the combination of
newer agents will be more effective in blood pressure
lowering and in achieving blood pressure control with
fewer side-effects than the combination of older drugs.
The trial is only running in countries in which the ran-
domized medications are marketed and available to
patients after they leave the trial. If our assumptions
hold true, they challenge the current recommendation of
the WHO/ISH [6] to start antihypertensive treatment
with diuretics in Black hypertensive patients. This pro-
gress report confirms that the number of patients rando-
mized in NOAAH reached approximately 80% of the
projected sample size. With the current rate of recruit-
ment and randomization, the final report will be avail-
able for publication in 2012.
Control of blood pressure to recommended target
levels below 140 mmHg systolic and 90 mmHg diastolic
remains a major challenge in Africa [21,22], Europe [23]
and the United States [24]. In the ongoing NOAAH trial,
within two weeks of randomization, the average blood
pressure fell from 153.9 to 136.3 mmHg systolic andfrom 91.5 to 81.3 mmHg diastolic, while over 65% of the
patients reached blood pressure control. Because
NOAAH does not include an untreated control group,
part of the blood pressure reduction might include pla-
cebo effects or habituation of the patients to the medical
environment and the clinical investigators. Because
blood pressure measurement is automated in NOAAH,
the primary endpoint is measured free of observer bias.
Lowering blood pressure [25-28] and early blood pres-
sure control [7,29] are essential for the prevention of
cardiovascular complications. NOAAH will generate in-
formation that will be helpful in addressing the epidemic
of cardiovascular disease in sub-Saharan Africa [30]. For
instance, we recently assessed the frequency and deter-
minants of in-hospital mortality among patients admit-
ted for hypertension to two city hospitals in Mbuji Mayi,
Congo [31]. Among 401 consecutive patients (mean age,
54.3 years; 129 women), 89 (22.2%) died over a median
follow-up of 15 days. The multivariable-adjusted prob-
ability of death increased with systolic pressure
(P= 0.0013) on admission [31]. In a Nigerian teaching
hospital in Enugu, the case-fatality rate among patients
admitted because of hypertension was 42.9% [32].
Undoubtedly, cost containment is important in the
management of a common disease, such as hyperten-
sion, especially in resource poor settings, where out-of-
pocket medical expenditure is usual practice. The basic
problem in the countries in which NOAAH is running,
is that many cheap generics are being sold with minimal
quality requirements or even without any regulation via
illegal channels. The situation is quite different from that
in South Africa, where very reputable pharmaceutical
companies from India, which have won US Food and
Drug Administration (FDA) approval, are marketing
high-quality generic drugs at a considerably lower cost
than the branded equivalents. While the older drugs are
cheaper, in the long run they contribute to the develop-
ment of side effects such as the metabolic syndrome,
diabetes mellitus, gout and dyslipidemia. More import-
antly, treatment with newer drugs results in lower risk
of morbidity and mortality [7]. The final NOAAH report
will include an economic analysis, but cannot address
cost-benefit in terms of hard cardiovascular outcomes,
because blood pressure control is the main outcome in
this trial with limited sample size and short follow-up.
By design, the NOAAH trial closely follows the ESC/
ESH [11] and several African [33-35] guidelines. First,
NOAAH patients have uncomplicated grade-1 or grade-
2 hypertension with no more than two additional risk
factors. For such patients, the guidelines [11,33-35]
propose that lifestyle changes should first be recom-
mended and reinforced for several weeks (grade 2) or
even months (grade 1) before antihypertensive drug
treatment is initiated. Second, as recommended by most
Table 1
Characteristic Older drugs Newer drugs Difference (95% CI) P
Number 69 71
Anthropometrics
Women, n [%] 33 (47.8) 42 (59.2) 0.23
Age, years 50.5 ± 8.6 50.9 ± 9.2 0.4 (−2.6 to 3.4) 0.78
Weight, kg 80.8 ± 14.6 76.9 ± 14.7 −4.0 (−8.9 to 0.9) 0.11
Height, cm 167.8 ± 7.8 166.4 ± 9.0 −1.2 (−4.1 to 1.6) 0.39
Body mass index, kg/m2 28.7 ± 4.6 27.8 ± 5.1 −0.9 (−2.5 to 0.8) 0.30
Waist circumference, cm 94.5 ± 13.9 92.9 ± 11.5 −1.6 (−5.9 to 2.7) 0.47
Sitting blood pressure
Systolic, mm Hg 154.2 ± 11.0 153.7 ± 11.8 −0.5 (−4.3 to 3.3) 0.80
Diastolic, mm Hg 92.2 ± 9.4 90.8 ± 10.3 −1.4 (−4.7 to 1.9) 0.41
Heart rate, beats/minute 74.0 ± 9.5 73.1 ± 10.3 −0.9 (−4.2 to 2.4) 0.59
Standing blood pressure
Systolic, mm Hg 154.9 ± 13.8 154.1 ± 12.8 −0.7 (−5.2 to 3.7) 0.74
Diastolic, mm Hg 97.1 ± 9.5 97.5 ± 10.2 0.4 (−2.9 to 3.7) 0.82
Heart rate, beats/minute 81.6 ± 9.5 80.6 ± 10.3 −1.0 (−4.7 to 2.7) 0.60
Lifestyle
Past smokers, n [%] 9 (13.2) 13 (18.3) 0.48
Current smokers, n [%] 3 (4.4 ) 1 (1.4 ) 0.35
Sniffing tobacco, n [%] 0 (0.0 ) 0 (0.0 ) 1.00
Current drinkers, n [%] 22 (32.4) 22 (31.0) 1.00
Blood measurements
Hemoglobin, mg/dL 12.9 ± 1.7 12.8 ± 1.7 −0.1 (−0.7 to 0.5) 0.74
Hematocrit, % 39.0 ± 5.0 38.8 ± 5.7 −0.2 (−2.0 to 1.7) 0.86
Glucose, mmol/L 5.1 ± 0.9 4.9 ± 0.7 −0.2 (−0.4 to 0.1) 0.19
Cholesterol, mmol/L 4.9 ± 1.1 4.8 ± 1.2 −0.0 (−0.4 to 0.4) 0.86
Creatinine, μmol/L 86.1 ± 20.1 90.9 ± 34.5 4.8 (−4.7 to 14.3) 0.32
ECG measurements
Sokolow-Lyon index, mm 28.1 ± 7.7 29.8 ± 7.2 1.7 (−0.8 to 4.2) 0.18
Cornell index, mm × msec 1818± 836 1771± 594 −48 (−290 to 194) 0.70
Values are mean ± SD, number of participants (%), or the difference between the two groups (95% confidence interval). Older and newer drugs refer to the
single-pill combinations of hydrochlorothiazide plus bisoprolol or valsartan plus amlodipine, respectively. The blood pressure measurements are averages of three
consecutive readings in each participant.
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used to initiate antihypertensive treatment in NOAAH
patients. Initiation of treatment with single-pill combi-
nations is particularly indicated when the blood pres-
sure is markedly above the hypertension threshold
(more than 20 mmHg systolic or 10 mmHg diastolic), or
in the presence of milder degrees of blood pressure ele-
vation in high-risk patients. Anticipated advantages of
this approach include tighter and earlier blood pressure
control, simplification of the therapeutic regimen and
therefore better adherence; avoidance of dose
dependent adverse effects experienced with higher
doses of single agents and attenuation of adverse effectsof some agents when used alone. The control of blood
pressure observed so far in NOAAH for the two treat-
ment groups combined and the low rate of adverse
events leading to withdrawal seem to confirm these
observations. Third, according to the ABCD algorithm
[39,40] both treatment arms of NOAAH include a drug
class that addresses the low-renin volume component of
hypertension (hydrochlorothiazide and amlodipine) as
well as agents (bisoprolol and valsartan) interfering with
the high-renin vasoconstrictor component [40].
Diuretics and calcium channel blockers potentiate the
efficacy of renin system inhibitors in Black low-renin
patients [41].
Table 2 Changes in blood pressure from baseline to follow-up.
Follow-up visit Baseline Follow-up Decrease (95% confidence interval )
2 weeks (n = 122)
Systolic pressure, mm Hg 154.4 ± 10.9 136.3 ± 14.2 18.2 (20.6 to 15.7)
Diastolic pressure, mm Hg 91.4 ± 10.3 81.3 ± 10.4 10.1 (11.8 to 8.4)
4 weeks (n = 109)
Systolic pressure, mm Hg 154.7 ± 10.9 135.3 ± 13.6 19.4 (22.1 to 16.7)
Diastolic pressure, mm Hg 91.8 ± 10.2 80.6 ± 9.3 11.2 (13.0 to 9.5)
8 weeks (n = 57)
Systolic pressure, mm Hg 153.5 ± 10.3 131.1 ± 11.8 22.4 (26.0 to 18.7)
Diastolic pressure, mm Hg 90.0 ± 9.3 77.8 ± 9.0 12.2 (14.7 to 9.6)
12 weeks (n = 49)
Systolic pressure, mm Hg 156.9 ± 11.0 131.1 ± 14.3 25.8 (30.1 to 21.5)
Diastolic pressure, mm Hg 93.9 ± 9.1 78.7 ± 11.4 15.2 (18.1 to 12.2)
Last visit (n = 129)a
Systolic pressure, mm Hg 154.4 ± 10.9 132.3 ± 14.4 22.1 (24.7 to 19.5)
Diastolic pressure, mm Hg 91.4 ± 10.1 79.0 ± 10.0 12.4 (14.2 to 10.7)
All changes in blood pressure were significant (P< 0.001).aSeven patients did not have a two-week visit. n, number.
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the combination of bisoprolol 5 mg plus hydrochlor-
othiazide 6.25 mg. Given once daily, this combination
lowers blood pressure throughout 24 hours and does so
significantly more than bisoprolol 5 mg/day or hydro-
chlorothiazide 25 mg/day given as single components
[42]. A double-blind parallel group dose escalation trial
involved 539 patients with uncomplicated mild-to-
moderate hypertension, who were randomized to the
combination of bisoprolol plus hydrochlorothiazide (2.5/
6.25, 5/6.25 and 10/6.25 mg/day, enalapril (5, 10, 20 mg/
day) or amlodipine (2.5, 5, 10 mg/day) for a period ofFigure 3 Systolic blood pressure (A), diastolic blood pressure (B) and
trial. For this analysis the two treatment groups were combined and all av
140 mmHg systolic and 90 mmHg diastolic.12 weeks [43]. The combination was at least as effective
as amlodipine and more effective than enalapril [43].
These findings were consistent in African Americans
[44].
The present study must be interpreted within the con-
text of its limitations. First, the current report originates
from a quality control program that was put in place to
monitor the clinical sites and to motivate the NOAAH
investigators. Second, the dose of hydrochlorothiazide in
the reference group is lower than has been used in posi-
tive outcome trials. In the comparison of the blood pres-
sure lowering effects, this might favor the valsartan plusthe proportion of patients controlled (C) during the course of the
ailable data were used. Blood pressure control is a level below
Figure 4 Systolic blood pressure (A), diastolic blood pressure (B) and the proportion of patients controlled (C) during the course of the
trial. For this cohort analysis the two treatment groups are combined and the number of patients was constant in each of the data points
(n = 49). Blood pressure control is a level below 140 mmHg systolic and 90 mmHg diastolic.
Odili et al. Trials 2012, 13:59 Page 8 of 11
http://www.trialsjournal.com/content/13/1/59amlodipine combination over the combination of biso-
prolol plus hydrochlorothiazide. Novartis made ExforgeW
available as 160 mg valsartan plus 5 mg or 10 mg amlo-
dipine. SCC had to purchase the reference drug on the
Belgian market. The only combination of older drugs, in
which the dosage of one component remained constant
over the dosing range (as valsartan in ExforgeW) was
LodozW: 6.25 mg hydrochlorothiazide plus 5 mg or
10 mg bisoprolol. In single-pill combinations, both com-
ponents potentiate one another. LodozW (ZiacW on the
US market) is FDA approved for the treatment of hyper-
tension (http://www.accessdata.fda.gov/drugsatfda_docs/
label/2011/020186s027s028lbl.pdf) in Blacks and non-
Blacks. LodozW is also on the market in the African
countries,where NOAAH is running. Third, clinical re-
search in developing countries differs in several ways
from that in developed countries, partly because of the
cultural differences, relatively poor health care and re-
search infrastructure, wide socioeconomic divide within
the society, low literacy level of the patients, and lack of
sufficient numbers of trained investigators and support
personnel in these countries [45]. For these reasons, we
did not implement self-measurement of blood pressure
at home. We also organized three investigators’ meetings
to overcome these difficulties and to familiarize the clin-
ical researchers with all aspects of the trial. The first
meeting took place in Paris, France, on 18 December
2008 with a follow-up meeting in Abuja, Nigeria, on 26
September 2009. A training workshop was organized in
Douala, Cameroon, on 26–27 August 2010. It took al-
most two years to obtain the required approvals, to
mount the required infrastructure and to train the clin-
ical investigators. Patient recruitment started on 1 Sep-
tember 2010. The procedures implemented for the trialboth peripherally at clinical sites and centrally at the
coordinating office worked well. Randomization
resulted in similar characteristics in the two treat-
ment groups. More than half of the randomized
patients were women, which will support the
generalizability of the NOAAH results. At the time of
submission of this progress report, enrollment was
completed and 180 randomized patients were in
follow-up. Finally, for the present analysis, we pooled
both treatment groups and we used simple statistics.
However, to increase power, the statistical analysis of
the NOAAH trial, once completed, will be based on
mixed models, which allow accounting for clustering
of repeated measures within a patient and for ran-
domly missing data.
Conclusions
Current guidelines support the use of combination ther-
apy as first-line treatment in hypertensive patients. How-
ever, to our knowledge, there is presently little
information on the blood pressure lowering efficacy and
the rate of adverse events on single-pill combinations
consisting of older drugs as compared with newer drugs
in Black hypertensive patients born and living in sub-
Saharan Africa. This progress report on the NOAAH
trial demonstrated that blood pressure control can be
achieved fast in Black African patients with a simple
regimen consisting of a single-pill combination of two
antihypertensive agents. It also shows that randomized
clinical trials of cardiovascular drugs can be conducted
among the indigenous populations of sub-Saharan Africa
by African investigators. The skills being learned by local
investigators will be useful for future more demanding
clinical trials.
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Yaoundé, Cameroon: HJ Boombhi, S Kingue; Douala,
Cameroon: MM Kamdem, JS Kaptue, D Lemogoum;
Libreville, Gabon: E Ecke Nzengue, JB Mipinda; Abidjan,
Ivory Coast: M Adoh Adoh, E Ake-Traboulsi; Ilorin, Ni-
geria: A Aderibigbe, PM Kolo, BA Omotoso; Enugu, Ni-
geria: BC Anisiuba, B Ezeala-Adikaibe, CK Ijoma, E Shu,
II Ulasi; Dakar, Senegal: SA Ba, MB Ndiaye.
Organization and coordination
Sponsor: JR M’Buyamba-Kabangu, S Mampunza Ma
Miezi (University of Kinshasa, Kinshasa, Democratic
Republic of Congo); Coordinating Center: K Asayama, B
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AN Odili, JA Staessen, L Thijs, S Zuba (University of
Leuven, Leuven, Belgium).
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